Phase 3 Trial of Bavencio in Ovarian Cancer is Terminated

Phase 3 Trial of Bavencio in Ovarian Cancer is Terminated
The immune checkpoint inhibitor Bavencio (avelumab) — given in combination and/or after platinum-based chemotherapy — is no better than chemotherapy alone at delaying disease progression or death in previously untreated women with advanced ovarian cancer, a Phase 3 trial shows. Merck KGaA (operating as EMD Serono in the U.S. and Canada) and Pfizer, which are developing Bavencio jointly, have decided to terminate the trial  called JAVELIN Ovarian 100 (NCT02718417). Health authorities have been notified about cessation of the study. Bavencio is an antibody that binds to the PD-L1 molecule, produced by cancer cells to prevent the immune system from recognizing them. By inhibiting PD-L1, Bavencio exposes the cancer cells, boosting the body’s immune surveillance mechanisms. In women diagnosed at advanced stages of ovarian cancer, the disease tends to progress despite platinum-based chemotherapy, the current first-line treatment for the condition. Thus, researchers investigated if Bavencio could improve the effectiveness of chemotherapy and help extend the time patients lived without signs of disease worsening. JAVELIN Ovarian 100 tested Bavencio in two regimens – in combination with first-line chemotherapy, or as a maintenance treatment after being given in combination with first-line chemotherapy. The trial included 998 women with locally advanced or metastatic epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who had not received prior treatments. Pa
Subscribe or to access all post and page content.

Tagged , , , , , .

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

Leave a Comment

Your email address will not be published. Required fields are marked *